Company logo

ATOS - Atossa Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
Seattle, United States
Type: Equity

ATOS price evolution
ATOS
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $79.64 $84.07 $88.57
Short term investments
Net receivables
Inventory
Total current assets $77.11 $81.72 $87.06 $92.22
Long term investments $1.71 $1.71 $1.71
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets $4.14 $4.03 $4.03
Total investments $1.71 $1.71 $1.71
Total assets $79.48 $85.86 $91.09 $96.25
Current liabilities
Accounts payable $1.56 $1.06 $1.23 $0.81
Deferred revenue
Short long term debt
Total current liabilities $5.8 $5.7 $5.33 $5.24
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $5.8 $5.7 $5.33 $5.24
Shareholders' equity
Retained earnings -$205.44 -$198.22 -$192.17 -$186.29
Other shareholder equity
Total shareholder equity $80.16 $85.76 $91.02
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $88.57 $111 $136.49 $39.66
Short term investments
Net receivables $0.74 $1.07 $0.63
Inventory
Total current assets $92.22 $118.2 $141.24 $42.77
Long term investments $1.71 $4.7
Property, plant & equipment $0.02 $0.04
Goodwill & intangible assets $0.01
Total noncurrent assets $4.03 $5.33 $0.02 $0.07
Total investments $1.71 $4.7
Total assets $96.25 $123.53 $141.26 $42.84
Current liabilities
Accounts payable $0.81 $2.96 $1.72 $1.59
Deferred revenue
Short long term debt $0.02
Total current liabilities $5.24 $5.57 $3.13 $15.67
Long term debt
Total noncurrent liabilities
Total debt $0.02
Total liabilities $5.24 $5.57 $3.13 $15.67
Shareholders' equity
Retained earnings -$186.29 -$156.19 -$129.23 -$111.9
Other shareholder equity $0.62
Total shareholder equity $91.02 $117.96 $138.14 $27.17
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $3.55 $3.75 $5.65
Selling, general & administrative $3.55 $3.23 $3.37
Total operating expenses $6.39 $7.11 $6.98 $9.02
Operating income -$7.11 -$6.98 -$9.02
Income from continuing operations
EBIT -$6.05 -$5.88 -$7.75
Income tax expense
Interest expense $1
Net income
Net income -$7.23 -$6.05 -$5.88 -$7.75
Income (for common shares) -$6.05 -$5.88 -$7.75
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $17.33 $15.08 $9.21 $6.61
Selling, general & administrative $14.04 $12.61 $11.31 $8
Total operating expenses $31.38 $27.69 $20.52 $14.61
Operating income -$31.38 -$27.69 -$20.52 -$14.61
Income from continuing operations
EBIT -$30.09 -$26.96 -$20.61 -$17.83
Income tax expense
Interest expense
Net income
Net income -$30.09 -$26.96 -$20.61 -$17.83
Income (for common shares) -$30.09 -$26.96 -$20.61 -$22.33
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income -$6.05 -$5.88 -$7.75
Operating activities
Depreciation $0 $0.01 $0.01
Business acquisitions & disposals
Stock-based compensation $0.35 $0.42 $0.52
Total cash flows from operations -$4.53 -$4.7 -$5.57
Investing activities
Capital expenditures -$0 -$0.01
Investments
Total cash flows from investing -$0.02 -$0 -$0.01
Financing activities
Dividends paid
Sale and purchase of stock $0.1 $0.2
Net borrowings
Total cash flows from financing $0.3 $0.1 $0.2
Effect of exchange rate
Change in cash and equivalents -$13.69 -$4.43 -$4.5 -$5.57
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$30.09 -$26.96 -$20.61 -$17.83
Operating activities
Depreciation $0.02 $0.01 $0.02 $0.05
Business acquisitions & disposals
Stock-based compensation $4.62 $6.79 $5.27 $3.02
Total cash flows from operations -$20.94 -$20.76 -$16.47 -$11.57
Investing activities
Capital expenditures -$0.01 -$0.03 -$0.01 -$0.01
Investments -$4.7
Total cash flows from investing -$0.01 -$4.73 -$0.01 -$0.01
Financing activities
Dividends paid
Sale and purchase of stock -$1.48 $113.88 $33.62
Net borrowings
Total cash flows from financing -$1.48 $113.3 $38.55
Effect of exchange rate
Change in cash and equivalents -$22.43 -$25.49 $96.82 $26.97
Fundamentals
Market cap $120.77M
Enterprise value N/A
Shares outstanding 125.80M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income -$26.91M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -4.49
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS -$0.21
ROA -30.52%
ROE N/A
Debt/Equity 0.06
Net debt/EBITDA N/A
Current ratio 13.30
Quick ratio N/A